Sutro Biopharma receives $10M milestone from Merck after first patient dosed in Phase 1 collaboration study

SUTRO BIOPHARMA, INC.

Merck pays Sutro $10.0 million milestone following first patient dosing in Phase 1 study of a collaboration candidate.
No other financial terms or guidance disclosed; collaboration continues.
Specific investigational candidate not named in the filing.
Milestone payment triggers positive cash inflow for Sutro's development programs.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.